共病失眠与OSA患者CPAP治疗中血压降低增强相关:前瞻性队列研究
该前瞻性队列研究纳入71例OSA伴血压升高的成人,接受4周自动CPAP治疗,按DSM-5标准分为COMISA组(n=22)和单纯OSA组(n=49)。
要点
- COMISA患者接受4周CPAP后24小时收缩压降低幅度显著大于单纯OSA患者。
- 失眠症状与达到临床有意义的24小时收缩压降低独立相关(调整OR 5.62)。
- COMISA患者需重视提高CPAP依从性的策略以优化心血管获益。
核心结论
- COMISA是CPAP治疗中收缩压降低反应增强的临床表型,尤其有助于实现临床有意义的24小时收缩压降低。
- 失眠是与此获益相关的独立因素,提示同时干预两种睡眠障碍可能优化心血管结局。
研究设计与样本
- 前瞻性队列研究,纳入71例OSA伴血压升高的成人,接受4周自动CPAP治疗。
- 按DSM-5标准分为COMISA组(n=22)和单纯OSA组(n=49)。
- 主要结局为临床有意义的24小时收缩压降低(下降≥5 mmHg)。
主要发现
- 日间和夜间收缩压降低在COMISA组同样一致获益。
- 失眠症状与主要结局独立相关(调整OR 5.62;95%CI 1.50-21.15)。
- 次要结局(24小时、日间和夜间收缩压降低)经Bonferroni校正(α=0.017)后关联不再显著。
临床怎么用
- 对OSA伴血压升高患者应筛查共病失眠,COMISA表型可能从CPAP治疗中获得更显著的收缩压降低。
- 需采取策略提高COMISA患者的CPAP依从性,以优化心血管获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comorbid insomnia and OSA (COMISA) is prevalent among patients with OSA and is linked to poorer BP control. However, its impact on the BP response to CPAP therapy remains unclear. RESEARCH QUESTION: Does the presence of comorbid insomnia modulate the antihypertensive effect of short-term CPAP therapy in patients with OSA? STUDY DESIGN AND METHODS: In this prospective cohort study, 71 adults with OSA and elevated BP underwent 4 weeks of auto-CPAP therapy. Participants were stratified into COMISA (n = 22) and OSA-alone (n = 49) groups based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria. The primary outcome was a clinically meaningful 24-hour systolic BP (SBP) reduction (decrease ≥ 5 mm Hg). Secondary outcomes included absolute changes in 24-hour, daytime, and nocturnal SBP and diastolic BP. RESULTS: Following 4 weeks of CPAP, the COMISA group achieved a significantly greater reduction in 24-hour SBP compared with the OSA-alone group (-6.0 ± 8.2 mm Hg vs -0.3 ± 6.5 mm Hg; P = .002), with consistent benefits in daytime and nocturnal SBP. Insomnia symptoms were independently associated with the primary outcome (adjusted OR, 5.62; 95% CI, 1.50-21.15). Associations with secondary outcomes (24-hour, daytime, and nocturnal SBP reductions) did not remain significant following Bonferroni adjustment (α = 0.017). INTERPRETATION: COMISA identifies a clinical phenotype with an enhanced SBP-lowering response to CPAP, particularly for achieving clinically meaningful 24-hour SBP reduction. Insomnia is an independent factor associated with this benefit, suggesting that addressing both sleep disorders may optimize cardiovascular outcomes. Strategies to improve CPAP adherence in COMISA are crucial. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry; No. ChiCTR2300067728.
引用
- Li S, Jiao Y, Zhou Z, et al. Comorbid Insomnia Is Associated With Enhanced BP Reduction With CPAP Therapy in Patients With OSA: A Prospective Cohort Study. Chest. 2026. PMID: 42537786. doi:10.1016/j.chest.2026.07.5226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。